All In Biotech

Drug Trial Radar · NCT00283946

A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia

FK199B (Zolpidem MR Tablet) Phase III Clinical Study -A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia -

Last checked: Nov 19, 2026Latest source record: Aug 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 876 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

876

Actual

Start

Feb 2006

Primary completion

Nov 2007

Study completion Nov 2007

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jan 31, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy and safety of FK199B (Zolpidem MR Tablet) in patients with insomnia by a randomized, double-blind, group-comparison study using zolpidem (Myslee) as a comparative drug

Conditions

  • Sleep Initiation and Maintenance Disorders
  • Sleep Disorders

Interventions

  • Zolpidem MRDrug

    Oral

  • ZolpidemDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean wake time after sleep onset during the double-blind periodTime frame: 2 Weeks

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Chubu Region, Japan

  • Site not named

    Chugoku Region, Japan

  • Site not named

    Hokkaido Region, Japan

  • Site not named

    Kansai Region, Japan

  • Site not named

    Kanto Region, Japan

  • Site not named

    Kyushu Region, Japan

  • Site not named

    Shikoku Region, Japan

  • Site not named

    Tohoku Region, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.